The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma.
H. Okada
No relevant relationships to disclose
P. Kalinski
No relevant relationships to disclose
A. H. Mintz
No relevant relationships to disclose
J. A. Engh
No relevant relationships to disclose
L. H. Butterfield
No relevant relationships to disclose
R. H. Hamilton
No relevant relationships to disclose
D. M. Potter
No relevant relationships to disclose
A. M. Salazar
Employment or Leadership Position - Oncovir (U)
F. S. Lieberman
No relevant relationships to disclose